BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 16, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 9, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company’s new Chief Financial Officer, effective

Strategic Leadership Addition Signals Drive to Expand Diagnostics Business BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 4, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 3, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47 th Annual Global

BILLERICA, Mass. --(BUSINESS WIRE)--May 26, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the “Inducement

BILLERICA, Mass. --(BUSINESS WIRE)--May 12, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company.

Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness BILLERICA, Mass. --(BUSINESS WIRE)--May 6, 2026-- Quanterix Corporation   (NASDAQ: QTRX), a company

Agreement supports the identification of patients eligible for Alzheimer’s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus’ clinical ordering platform BILLERICA, Mass. --(BUSINESS WIRE)--May 6, 2026-- Lucent Diagnostics, a brand of

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 24, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m.

Novel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer LAGUNA HILLS, Calif. & BILLERICA, Mass. --(BUSINESS WIRE)--Apr.